Endothelins in physiology and pathology of the kidney;Rola endotelin w fizjologii i patologii nerek

Advances in Clinical and Experimental Medicine

Volumn 12, Issue 1, 2003, Pages 81-86

  Łapiński, Radosław ^a  

^a Klinika Chirurgii Naczyn   (Poland)

Author keywords

Endothelins; Kidney

Indexed keywords

AMINO ACID DERIVATIVE; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; G PROTEIN COUPLED RECEPTOR; ISOPROTEIN; PEPTIDE DERIVATIVE;

EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FUNCTION; MESANGIUM CELL; NEPHRON; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN FAMILY; REVIEW; SODIUM ABSORPTION; VASOCONSTRICTION; WATER ABSORPTION;

GLOMERULUS;

EID: 0037221693     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kabayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332, 411-415.
2. Backer A., Bokemeyer D., Kramer H. J.: Endothelin synthesis and receptors in porcine kidney. Acta Physiol. Scand. 2001, 171, 105-112.
3. Kohan D. E.: Endothelins in the normal and diseased kidney. Am. J. Kidney Dis. 1997, 29, 2-26.
4. Masaki T., Miwa S., Sawamura T., Ninomiya H., Okamoto Y.: Subcellular mechanisms of endothelin action in vascular system. Eur. J. Pharmacol. 1999, 375, 133-138.
5. Catalan R. E., Martinez A. M., Aragones M. D., Martinez A., Diaz G.: Endothelin stimulates phosphoinositide hydrolysis and PAF synthesis in brain microvessels. J. Cerebr. Blood Flow Metabol. 1996, 16, 1325-1334.
6. Rosen B., Barg J., Zimlichman R.: The effects of angiotensin II, endothelin-1 and protein kinase C inhibitor on DNA synthesis and intracellular calcium mobilization in vascular smooth muscle cells from young normotensive and spontaneously hypertensive rats J. Hypertens. 1999, 12, 1243-1251.
7. Ehrenreich H., Anderson R. W., Fox C. H., Rieckmann P., Hoffman G. S., Travis W. D., Coligan J. E., Kehri J. H., Fauci A. S.: Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J. Exp. Med. 1990, 172, 1741-1748.
8. Lee C. Y., Chiappinelli V. A., Takasaki C., Yanagisawa M., Kimura S., Goto K., Masaki T.: Similarity of endothelin to snake venom toxin. Nature 1988, 335, 303.
9. Sugo S., Minamino N., Shoji H., Isumi Y., Nakao K., Kangawa K., Matsuo H.: Regulation of endothelin-1 production in cultured rat vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 2001, 37, 25-40.
10. Chanda J., Brichkov I., Canver C. C.: Prevention of radial artery graft vasospasm after coronary bypass. Ann. Thorac. Surg. 2000, 70, 2070-2074.
11. Evans R. G., Madden A. C., Oliver J. J., Levis T. V.: Effects of ETA- and ETB-receptor antagonists on regional kidney blood flow, and responses to intravenous endothelin-1, in anaesthetized rabbits. J Hypertens. 2001, 19, 1789-1799.
12. B receptor-mediated constriction in the renal microcirculation of rats. J. Physiol. 1996, 497, 211-218.
13. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994, 89, 1203-1208.
14. Goetz K. L., Wang B. C., Madwed J. B., Zhu J. L., Leadley R. J.: Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs. Am. J. Physiol. 1988, 255, RI064-RI068.
15. Knapik-Kordecka M., Adamiec R., Ciosek W.: Endotelina-1 w patogenezie zespołu Raynauda. Pol. Merk. Lek. 2001, 10 (60), 424-425.
16. Drexler H., Homig B.: Endothelial dysfunction in human disease. J. Mol. Cell. Cardiol. 1999, 31, 51-60.
17. Ouvina S. M., La Greca. R. D., Zanaro N. L., Palmer L., Sassetti B.: Endothelial dysfunction, nitric oxide and platelet aggregation in hypertensive and diabetic type II patients. Thromb. Res. 2001, 102, 107-114.
18. Klahr S.: Mechanisms of progression of chronic renal damage. J. Nephrol. 1999, 12, S53-S62.
19. Clavell A. L., Bumeti J. C.: Physiologic and pathophysiologic roles endothelin in the kidney. Curr. Opin. Nephrol. Hypertens. 1994, 3, 66-72.
20. Rossi G. P., Sacchetto A., Cesari M., Pessina A. C.: Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc. Res. 1999, 43, 300-307.
21. Wenzel R. R., Ruthemann J., Bruck H., Schafers R. F., Michel M. C., Phillip T.: Endothelin-1 receptor antagonist inhibits angiotensin II and noradrenaline. Br. J. Clin. Pharmacol. 2001, 52, 151-157.
22. B receptor antagonism during cold preservation in renal transplantation. Transplantation 2001, 71, 619-627.
23. Chua B. H. L., Chua C. C., Digilo C. A., Siu B. B.: Regulation of endothelin-1 mRNA by angiotensin 11 in rat heart endothelial cells. Biochim. Biophys. Acta 1993, 1178, 201-206.
24. Ais G., Novo C., Lopez-Farre A., Romeo J. M., Lopez-Novoa J. M.: Effect of endothelin on systemic and regional hemodynamics in rat. Eur. J. Pharmacol. 1989, 170, 113-116.
25. Sorensen S. S., Madsen J. K., Pedersen E. B.: Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am. J. Physiol. 1994, 266, F411-F418.
26. Honing M. L., Hijmering M. L., Ballard D. E., Yang Y. P., Padley R. J., Morrison P. J., Rabelink T. J.: Selective ET(A) receptor antagonism with ABT-27 attenuates all renal effects of endothelin in humans. J. Am. Soc. Nephrol. 2000, 11, 1498-1504.
27. Takenaka, T., Forster H., Epstein M.: Protein kinase C and calcium channel activation as determinants of renal vasoconstriction by angiotensin II and endothelin. Circ. Res. 1993, 73, 743-750.
28. Tamaoki T., Nomoto H., Takahashi I., Kato Y., Moromoto M., Tomita F.: Staurosporine a potent inhibitor of phospholipid/Ca dependent protein kinase. Biochem. Biophys. Res. Commun. 1986, 135, 397-402.
29. Lapinski R., Benigni A., Perico N., Remuzzi G.: Angiotensin II increases albumin glomerular permeability in isolated perfused rat kidney by a mechanism which is independent from endothelin-1. J. Am. Soc. Nephrol. 1994, 5, 662.
30. Kelly J. J., Whitworth J. A.: Endothelin as mediator in cardiovascular disease. Clin. Exp. Pharmacol. Physiol. 1999, 26, 158-161.
31. Duggan A. E., Stack W., Hull M., Filipowicz B., Knifton A., Crome R., Weber R., Bishop A., Polak J., Hawkey C. J.: Protection against aspirin-induced human mucosal injury by bosentan, a new endothelin-1 receptor antagonist. Aliment. Pharmacol. Ther. 1999, 13, 631-635.
32. Clozel M.: Endothelin receptor antagonists: current status and perspectives. J. Cardiovasc. Pharmacol. 2000, 35, S65-S68.